Mark Foletta
Directeur/Membre du Conseil chez DEXCOM, INC.
Fortune : 10 M $ au 30/04/2024
Profil
Mr. Mark G.
Foletta, CPA, is an Independent Director at Enanta Pharmaceuticals, Inc., a Lead Independent Director at DexCom, Inc., an Independent Director at AMN Healthcare Services, Inc., a Member at Corporate Directors Forum and a Member at The Financial Executives Institute.
He is on the Board of Directors at Enanta Pharmaceuticals, Inc., DexCom, Inc. and AMN Healthcare Services, Inc. Mr. Foletta was previously employed as a Chief Financial Officer & Executive Vice President by Tocagen, Inc., a Chief Financial & Accounting Officer by Biocept, Inc., an Independent Director by Ambit Biosciences Corp., an Independent Director by Regulus Therapeutics, Inc., an Independent Director by Anadys Pharmaceuticals, Inc., a Chief Financial Officer & Senior VP-Finance by Amylin Pharmaceuticals, Inc., a Principal by Triton Group Management, Inc., an Audit Manager by Ernst & Young LLP, a Chief Financial Officer, Secretary & Senior VP by Intermark, Inc., and a Chief Financial Officer, Secretary & Senior VP by Triton Group Ltd.
He also served on the board at ViaCyte, Inc. and Islet Sciences, Inc. He received his undergraduate degree from the University of California, Santa Barbara.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DEXCOM, INC.
0,02% | 22/05/2024 | 65 371 ( 0,02% ) | 9 M $ | 30/04/2024 |
| 19/04/2024 | 10 254 ( 0,03% ) | 576 788 $ | 30/04/2024 | |
| 06/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Mark Foletta
| Sociétés | Poste | Début |
|---|---|---|
| AMN HEALTHCARE SERVICES, INC. | Directeur/Membre du Conseil | 12/12/2012 |
| DEXCOM, INC. | Directeur/Membre du Conseil | 19/11/2014 |
| ENANTA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 29/06/2020 |
Corporate Directors Forum
 Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Corporate Officer/Principal | - |
| The Financial Executives Institute | Corporate Officer/Principal | - |
Anciens postes connus de Mark Foletta
| Sociétés | Poste | Fin |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/09/2022 |
| FORTE BIOSCIENCES, INC. | Directeur Financier/CFO | 15/06/2020 |
| REGULUS THERAPEUTICS INC. | Directeur/Membre du Conseil | 31/05/2018 |
| BIOCEPT, INC. | Directeur Financier/CFO | 27/07/2016 |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Mark Foletta
| University of California, Santa Barbara | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| REGULUS THERAPEUTICS INC. | Health Technology |
| AMN HEALTHCARE SERVICES, INC. | Commercial Services |
| DEXCOM, INC. | Health Technology |
| BIOCEPT, INC. | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
| The Financial Executives Institute | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Islet Sciences, Inc.
 Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA. | Commercial Services |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Corporate Directors Forum
Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Commercial Services |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
